[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100540241":3},{"organization":4,"outcomesModule":7,"designInfo":30,"detailedDescription":33,"studyPopulation":34,"armGroups":29,"interventions":29,"overallOfficials":29,"centralContacts":35,"locations":41,"responsibleParty":281,"collaborators":29,"id":283,"slug":284,"hasResults":285,"nctId":286,"briefTitle":287,"officialTitle":288,"acronym":289,"eligibilityCriteria":290,"healthyVolunteers":285,"sex":291,"minAge":292,"maxAge":29,"enrollmentInfo":293,"targetDuration":29,"studyType":296,"phases":29,"briefSummary":297,"conditions":298,"keywords":300,"overallStatus":109,"whyStopped":29,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":307,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":314,"locationsCount":315},{"fullName":5,"class":6},"AstraZeneca","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":29,"otherOutcomes":29},[9,13,16,19,22,26],{"measure":10,"description":11,"timeFrame":12},"PGA","Physician's overall assessment of disease activity on a visual analog scale ranging from 0 (no activity) to 3 (severe activity).","Baseline (pre-infusion) Month 1, Month 3, Month 6, Month 12",{"measure":14,"description":15,"timeFrame":12},"SLEDAI-2K","24 lupus-related (weighted) items to assess disease activity, rated as 'present' or 'absent' and attributed to active lupus. Scored on a scale from 0 to 105, with 0 being inactive disease.",{"measure":17,"description":18,"timeFrame":12},"CLASI","Skin activity and damage assessment completed by physician by scoring each specific area as indicated on the form. The higher the score, the worse the activity\u002Fdamage.",{"measure":20,"description":21,"timeFrame":12},"FACIT-Fatigue","A 13-item questionnaire to assess the impact of fatigue on a 5-point verbal rating scale. Scores range from 0 to 52; a higher score indicates les fatigue",{"measure":23,"description":24,"timeFrame":25},"LupusQoL","A 34-item questionnaire on a verbal rating scale covering several domains, including daily activities, pain, fatigue and sleep in relation to lupus symptoms.","Baseline (pre-infusion) Month 3, Month 6, Month 12",{"measure":27,"description":28,"timeFrame":25},"EQ-5D-5L","5-item questionnaire measuring 5 dimensions of general health status on a verbal rating, and a single visual analog scale about overall perceived health today",null,{"allocation":29,"interventionModel":29,"interventionModelDescription":29,"primaryPurpose":29,"observationalModel":31,"timePerspective":32,"maskingInfo":29},"COHORT","PROSPECTIVE","INTERSTELLAR is a multi-country, single-arm, observational, cohort study, with 1 year retrospective baseline data and 1 year of prospective follow-up. The study will be initiated on a country-by-country basis following the commercial launch of anifrolumab. The enrolment period is anticipated to be 12 months per country. In general, patients will enter the study between the first anifrolumab prescription and infusion (index), with follow-up until death, loss to follow-up, patient discontinuing the study, or end of study period (whichever occurs first). Relevant clinical and patient reported outcome (PRO) data collection for the entire follow up will continue for patients who have discontinued anifrolumab during the study, unless the patients have withdrawn their consent for participation in the study","10 to 50 patients will be enrolled per country from academic, community and hospital outpatient settings, to maximize the representation of the study population. This will result in approximately 180-200 patients in total allowing for sufficient precision when analysing the total cohort and to explore subgroups of interest.",[36],{"name":37,"role":38,"phone":39,"phoneExt":29,"email":40},"AstraZeneca Clinical Study Information Center","CONTACT","1-877-240-9479","information.center@astrazeneca.com",[42,54,61,71,78,85,92,99,108,118,125,134,143,150,154,161,165,172,179,186,195,204,211,220,229,233,240,247,256,263,267,274],{"facility":43,"status":44,"city":45,"state":29,"zip":29,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":29},"Research Site","ACTIVE_NOT_RECRUITING","Buenos Aires","Argentina","AR",{"type":49,"coordinates":50},"Point",[51,52],-58.37723,-34.61315,{"lat":52,"lon":51},{"facility":43,"status":44,"city":55,"state":29,"zip":29,"country":46,"countryCode":47,"cosmosGeoPoint":56,"geoPoint":60,"contacts":29},"Córdoba",{"type":49,"coordinates":57},[58,59],-64.18853,-31.40648,{"lat":59,"lon":58},{"facility":43,"status":62,"city":63,"state":29,"zip":29,"country":64,"countryCode":65,"cosmosGeoPoint":66,"geoPoint":70,"contacts":29},"WITHDRAWN","Guangzhou","China","CN",{"type":49,"coordinates":67},[68,69],113.25,23.11667,{"lat":69,"lon":68},{"facility":43,"status":44,"city":72,"state":29,"zip":29,"country":64,"countryCode":65,"cosmosGeoPoint":73,"geoPoint":77,"contacts":29},"Hong Kong",{"type":49,"coordinates":74},[75,76],114.17469,22.27832,{"lat":76,"lon":75},{"facility":43,"status":62,"city":79,"state":29,"zip":29,"country":64,"countryCode":65,"cosmosGeoPoint":80,"geoPoint":84,"contacts":29},"Shenzhen",{"type":49,"coordinates":81},[82,83],114.0683,22.54554,{"lat":83,"lon":82},{"facility":43,"status":44,"city":86,"state":29,"zip":29,"country":64,"countryCode":65,"cosmosGeoPoint":87,"geoPoint":91,"contacts":29},"Zhongshan",{"type":49,"coordinates":88},[89,90],113.37912,22.52306,{"lat":90,"lon":89},{"facility":43,"status":62,"city":93,"state":29,"zip":29,"country":64,"countryCode":65,"cosmosGeoPoint":94,"geoPoint":98,"contacts":29},"Zhuhai",{"type":49,"coordinates":95},[96,97],113.56778,22.27694,{"lat":97,"lon":96},{"facility":43,"status":44,"city":100,"state":29,"zip":29,"country":101,"countryCode":102,"cosmosGeoPoint":103,"geoPoint":107,"contacts":29},"San José","Costa Rica","CR",{"type":49,"coordinates":104},[105,106],-84.08489,9.93388,{"lat":106,"lon":105},{"facility":43,"status":109,"city":110,"state":29,"zip":29,"country":111,"countryCode":112,"cosmosGeoPoint":113,"geoPoint":117,"contacts":29},"RECRUITING","Alexandria","Egypt","EG",{"type":49,"coordinates":114},[115,116],29.91582,31.20176,{"lat":116,"lon":115},{"facility":43,"status":109,"city":119,"state":29,"zip":29,"country":111,"countryCode":112,"cosmosGeoPoint":120,"geoPoint":124,"contacts":29},"Cairo",{"type":49,"coordinates":121},[122,123],31.24967,30.06263,{"lat":123,"lon":122},{"facility":43,"status":44,"city":126,"state":29,"zip":29,"country":127,"countryCode":128,"cosmosGeoPoint":129,"geoPoint":133,"contacts":29},"Guatemala City","Guatemala","GT",{"type":49,"coordinates":130},[131,132],-90.51327,14.64072,{"lat":132,"lon":131},{"facility":43,"status":44,"city":135,"state":29,"zip":29,"country":136,"countryCode":137,"cosmosGeoPoint":138,"geoPoint":142,"contacts":29},"Aktobe","Kazakhstan","KZ",{"type":49,"coordinates":139},[140,141],57.20718,50.27969,{"lat":141,"lon":140},{"facility":43,"status":44,"city":144,"state":29,"zip":29,"country":136,"countryCode":137,"cosmosGeoPoint":145,"geoPoint":149,"contacts":29},"Almaty",{"type":49,"coordinates":146},[147,148],76.9115,43.25249,{"lat":148,"lon":147},{"facility":43,"status":62,"city":144,"state":29,"zip":29,"country":136,"countryCode":137,"cosmosGeoPoint":151,"geoPoint":153,"contacts":29},{"type":49,"coordinates":152},[147,148],{"lat":148,"lon":147},{"facility":43,"status":44,"city":155,"state":29,"zip":29,"country":136,"countryCode":137,"cosmosGeoPoint":156,"geoPoint":160,"contacts":29},"Astana",{"type":49,"coordinates":157},[158,159],71.44598,51.1801,{"lat":159,"lon":158},{"facility":43,"status":62,"city":155,"state":29,"zip":29,"country":136,"countryCode":137,"cosmosGeoPoint":162,"geoPoint":164,"contacts":29},{"type":49,"coordinates":163},[158,159],{"lat":159,"lon":158},{"facility":43,"status":44,"city":166,"state":29,"zip":29,"country":136,"countryCode":137,"cosmosGeoPoint":167,"geoPoint":171,"contacts":29},"Pavlodar",{"type":49,"coordinates":168},[169,170],76.96881,52.27601,{"lat":170,"lon":169},{"facility":43,"status":44,"city":173,"state":29,"zip":29,"country":136,"countryCode":137,"cosmosGeoPoint":174,"geoPoint":178,"contacts":29},"Semey",{"type":49,"coordinates":175},[176,177],80.25025,50.42064,{"lat":177,"lon":176},{"facility":43,"status":44,"city":180,"state":29,"zip":29,"country":136,"countryCode":137,"cosmosGeoPoint":181,"geoPoint":185,"contacts":29},"Shymkent",{"type":49,"coordinates":182},[183,184],69.60042,42.30988,{"lat":184,"lon":183},{"facility":43,"status":109,"city":187,"state":29,"zip":29,"country":188,"countryCode":189,"cosmosGeoPoint":190,"geoPoint":194,"contacts":29},"Kuwait City","Kuwait","KW",{"type":49,"coordinates":191},[192,193],47.97429,29.367,{"lat":193,"lon":192},{"facility":43,"status":109,"city":196,"state":29,"zip":29,"country":197,"countryCode":198,"cosmosGeoPoint":199,"geoPoint":203,"contacts":29},"Mexico City","Mexico","MX",{"type":49,"coordinates":200},[201,202],-99.12766,19.42847,{"lat":202,"lon":201},{"facility":43,"status":109,"city":205,"state":29,"zip":29,"country":197,"countryCode":198,"cosmosGeoPoint":206,"geoPoint":210,"contacts":29},"Mérida",{"type":49,"coordinates":207},[208,209],-89.62318,20.967,{"lat":209,"lon":208},{"facility":43,"status":44,"city":212,"state":29,"zip":29,"country":213,"countryCode":214,"cosmosGeoPoint":215,"geoPoint":219,"contacts":29},"Muscat","Oman","OM",{"type":49,"coordinates":216},[217,218],58.40778,23.58413,{"lat":218,"lon":217},{"facility":43,"status":44,"city":221,"state":29,"zip":29,"country":222,"countryCode":223,"cosmosGeoPoint":224,"geoPoint":228,"contacts":29},"Doha","Qatar","QA",{"type":49,"coordinates":225},[226,227],51.53096,25.28545,{"lat":227,"lon":226},{"facility":43,"status":44,"city":230,"state":29,"zip":29,"country":231,"countryCode":232,"cosmosGeoPoint":29,"geoPoint":29,"contacts":29},"ASIR","Saudi Arabia","SA",{"facility":43,"status":44,"city":234,"state":29,"zip":29,"country":231,"countryCode":232,"cosmosGeoPoint":235,"geoPoint":239,"contacts":29},"Jeddah",{"type":49,"coordinates":236},[237,238],39.18624,21.49012,{"lat":238,"lon":237},{"facility":43,"status":44,"city":241,"state":29,"zip":29,"country":231,"countryCode":232,"cosmosGeoPoint":242,"geoPoint":246,"contacts":29},"Riyadh",{"type":49,"coordinates":243},[244,245],46.72185,24.68773,{"lat":245,"lon":244},{"facility":43,"status":44,"city":248,"state":29,"zip":29,"country":249,"countryCode":250,"cosmosGeoPoint":251,"geoPoint":255,"contacts":29},"Kaohsiung City","Taiwan","TW",{"type":49,"coordinates":252},[253,254],120.31333,22.61626,{"lat":254,"lon":253},{"facility":43,"status":44,"city":257,"state":29,"zip":29,"country":249,"countryCode":250,"cosmosGeoPoint":258,"geoPoint":262,"contacts":29},"Taichung",{"type":49,"coordinates":259},[260,261],120.6839,24.1469,{"lat":261,"lon":260},{"facility":43,"status":62,"city":257,"state":29,"zip":29,"country":249,"countryCode":250,"cosmosGeoPoint":264,"geoPoint":266,"contacts":29},{"type":49,"coordinates":265},[260,261],{"lat":261,"lon":260},{"facility":43,"status":44,"city":268,"state":29,"zip":29,"country":249,"countryCode":250,"cosmosGeoPoint":269,"geoPoint":273,"contacts":29},"Taipei",{"type":49,"coordinates":270},[271,272],121.52639,25.05306,{"lat":272,"lon":271},{"facility":43,"status":44,"city":275,"state":29,"zip":29,"country":249,"countryCode":250,"cosmosGeoPoint":276,"geoPoint":280,"contacts":29},"Taoyuan",{"type":49,"coordinates":277},[278,279],121.29696,24.99368,{"lat":279,"lon":278},{"type":282,"investigatorFullName":29,"investigatorTitle":29,"investigatorAffiliation":29,"oldNameTitle":29,"oldOrganization":29},"SPONSOR","100540241","interstellar---international-study-evaluating-lupus-outcomes-after-anifrolumab-real-world-use-100540241",false,"NCT06314282","INTERSTELLAR - International Study Evaluating Lupus Outcomes After Anifrolumab Real World Use","INTERSTELLAR - Multi-National, Observational, Prospective, Post-Launch, Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical Practice","INTERSTELLAR","Inclusion Criteria:\n\n1. Aged 18 years or older at study enrolment.\n2. Fulfilled the 2019 EULAR\u002FACR criteria1 for SLE at the time of study entry.\n3. Prescribed anifrolumab for their SLE treatment for the first time, according to approved country-specific label.\n4. It is important to note that a physician decision to prescribe anifrolumab will need to occur prior to any study-related discussion.\n5. In countries where prescription reimbursements are authorized on a case-by-case basis, authorization (ie, patient access to treatment) will be required for study entry.\n6. Provided informed consent to participate in the study.\n7. Willing and able to participate in all required study evaluations and procedures.\n\nExclusion Criteria:\n\n1. Currently participating in an anifrolumab early access\u002Fcompassionate use program or an interventional clinical trial with an investigational product.\n2. Previous exposure to anifrolumab as part of a clinical trial or early access program.\n3. Documented diagnosis of severe or rapidly progressive Class III or IV glomerulonephritis requiring induction therapy (mycophenolate mofetil \\[MMF\\]\u002Fcyclophosphamide \\[CYC\\] + high dose steroids), isolated Class V lupus nephritis, or active severe or unstable neuropsychiatric lupus.\n4. Any other condition which the investigator deems to limit a patient's ability to understand the informed consent or complete the PROs.","ALL","18 Years",{"count":294,"type":295},200,"ESTIMATED","OBSERVATIONAL","INTERSTELLAR study will generate critical prospective real-world evidence on the benefits of adding Anifrolumab to standard of care treatment for SLE in routine clinical practice, to inform physicians, payers and patients. The study will use clinical assessments that are relevant for SLE-treating physicians in routine clinical practice, as well as introduce a specific measure for skin manifestations to affirm the potency of anifrolumab in treating SLE-related skin manifestations. The study will use standardized objectives, inclusion\u002Fexclusion criteria and outcome measures across all countries participating in this study including GCC (Qatar, KSA), Mexico, CAMCAR (Costa Rica, Panama, Dominican Republic), Colombia, Argentina, Taiwan, and Egypt, and any other countries that may be included in the study, in order to facilitate a comparison and analysis across all countries included in this study.",[299],"Systemic Lupus Erythematosus (SLE)",[301,302,303,304,305],"SLE","Systemic lupus erythematosus","autoimmune disease","Lupus","Anifrolumab","2026-07-16",{"date":308,"type":309},"2026-07-17","ACTUAL",{"date":311,"type":309},"2024-10-22",{"date":313,"type":295},"2027-12-31",{"name":5,"class":6},32]